- CMS seeks to close Medicare negotiation 'loophole'CMS has proposed a policy change that clarifies its stance on how products are grouped together for Medicare negotiations. Under the Inflation Reduction Act, biologics become eligible for Medicar…Endpoints · 1mo ago↗ source
- FDA plans to keep Makary priorities on trials, China, deputy saysPHILADELPHIA – Following the recent departures of FDA Commissioner Marty Makary and both of his center directors for drugs and biologics, the Trump administration will continue pushing their priori…Endpoints · 1mo ago↗ source
- Takeda fortifies orexin potential with more Phase 3 dataWith a formidable new competitor set to enter the orexin development race, Takeda is out with new data that it hopes will reinforce market-leading potential. The additional results from Takeda’s…